Sharemaestro Newsreel

EU Approves Sanofi's MenQuadfi for Infants as Young as 6 Weeks, Expanding Protection Against a Leading Cause of Acquired Deafness

The European Commission has approved Sanofi's MenQuadfi vaccine for use in infants as young as 6 weeks, expanding protection against invasive meningococcal disease. This decision is significant for hearing healthcare professionals, as the disease is a leading cause of acquired sensorineural hearing loss in …

Merck (MRK) tech chief exercises 52,847 stock options, sells all shares

David Michael Williams, EVP and Chief Information & Digital Officer at Merck & Co., Inc. (MRK), exercised 52,847 stock options on August 5, 2026, at various strike prices. He subsequently sold all 52,847 shares at a weighted average price of $128.7707, generating approximately $2.87 …

Merck & Co., Inc. 2026: Revenue $16.61B, EPS ($0.54) — 10-Q Summary

Merck & Co., Inc. reported Q2 2026 results with revenue of $16.61 billion, a 5.1% increase year-over-year, but net income swung to a loss of ($1.34 billion) and diluted EPS was ($0.54). Revenue growth was driven by oncology, cardiometabolic/respiratory products, and animal health, with …

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part of Novo Nordisk) that FDA classified the April 2026 site inspection of Catalent Indiana fill-finish facility as Official Action Indicated (OAI) Scholar Rock continuing to collaborate closely with FDA and …

AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed

In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie …

Scilex Holding Company Revenue Breakdown – BOATS:SCLXW

This article provides a revenue breakdown for Scilex Holding Company (SCLXW). It highlights that the United States was the primary contributor to its revenue, accounting for $30.25 million last year and $56.59 million the year before. The data is presented from a financial overview …

Merck (NYSE: MRK) EVP Guindo Chirfi sells 15,000 company shares

Merck & Co., Inc. EVP Guindo Chirfi sold 15,000 shares of common stock on August 6, 2026, at a price of $131.00 per share. This transaction, classified as an open-market or private sale, resulted in Chirfi directly owning 46,613 shares of Merck common stock …

Novo Nordisk Stock Rises After GLP-1 Antitrust Win

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge threw out an antitrust lawsuit against Novo and Eli Lilly (NYSE:LLY). According to Reuters, …

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound

Key Points Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. There are several other reasons to consider the stock, despite the potential headwinds ahead. 10 stocks we like better than Pfizer › The past few years have been …

Is Biogen (BIIB) Fully Priced After Earnings Raised Revenue But Cut Profit?

Biogen (BIIB) recently reported Q2 2026 earnings with higher sales but lower net income, raising questions about its current valuation. Despite a 61.47% shareholder return over the past year, the stock is considered 9.4% undervalued by analysts based on long-term growth for its Alzheimer's …

Roche Stock Jumps as Morgan Stanley Sees Drug Breakout

This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. …

Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of …

Catalyst Watch: Inflation reads, AMAT earnings, Google Pixel event, and MLB on Netflix

[Lower Manhattan Cityscape] Art Wager/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - AUGUST 10 * …

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics DNLI reported a second-quarter 2026 loss of 68 cents per share, narrower than the Zacks Consensus Estimate of a loss of 73 cents. The company incurred a loss of 72 cents in the year-ago quarter. In late March, Denali secured a major …

CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong

Cytokinetics, Incorporated CYTK reported a second-quarter 2026 loss of $1.50 per share, narrower than the Zacks Consensus Estimate of a loss of $1.63 per share. In the year-ago quarter, the company reported a loss of $1.12 per share. Loss widened year over year due …

NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised

Novavax NVAX incurred a loss of 32 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 36 cents. In the year-ago quarter, the company had recorded earnings per share (EPS) of 62 cents, driven …

How Merck & Company Inc. (MRK) Affects Rotational Strategy Timing

This article analyzes Merck & Company Inc. (MRK) for rotational strategy timing, indicating a neutral sentiment for near and mid-term, with a potential long-term positive bias. It highlights a significant short setup opportunity with a 25.3:1 risk-reward ratio and provides distinct AI-generated trading strategies …

How Pfizer Thinks About AI

Albert Bourla, CEO of Pfizer, outlines the company's ambition to be the most AI-forward in the pharmaceutical industry. He details three key strategies: structuring 177 years of data, federating AI across the organization to empower employees, and investing in AI fluency for all colleagues. …

Trade Tracker: Kevin Simpson buys more Amgen

Kevin Simpson, founder and CIO of Capital Wealth Planning, has increased his holdings in Amgen. He discussed his rationale for buying more shares at current price levels during an appearance on CNBC's 'Halftime Report.' The article primarily features a video clip of his explanation.

Biogen, Investors Reach Settlement Outline Over Alzheimer’s Drug

Biogen has reached a preliminary settlement agreement with investors who filed a class-action lawsuit alleging the company misrepresented clinical trial data for its Alzheimer's drug, Aduhelm. The terms of the settlement, including the financial amount, are not yet public but are expected to be …

Biogen closes deal for USD 1b buyout of RayThera

Biogen has completed its acquisition of RayThera Inc., a San Diego-based small-molecule immunology company, for up to $1 billion. This deal adds multiple anti-inflammatory assets to Biogen's pipeline, with the lead program having entered Phase I development in July 2026. This acquisition is Biogen's …

‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth

Karsten Munk Knudsen, CFO of Novo Nordisk, described his nine years on the leadership team as a "roller coaster," navigating periods of low growth, hyper-growth fueled by demand for their obesity drugs, and subsequent growth slowdown. He emphasized the pressure and responsibility of steering …

Amgen Inc. $AMGN Shares Acquired by Czech National Bank

The Czech National Bank increased its stake in Amgen Inc. by 4.8% in the second quarter, acquiring an additional 6,969 shares and bringing its total holdings to 153,622 shares valued at $55.6 million. This comes as Amgen reported strong second-quarter results, exceeding analyst expectations …

PensionDanmark Pensionsforsikringsaktieselskab Grows Stake in Amgen Inc. $AMGN

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Amgen Inc. by 12.3% in the second quarter, bringing its total ownership to 108,300 shares valued at approximately $39.2 million. This comes as Amgen reported strong quarterly results, with a 9.5% revenue increase and raised 2026 adjusted EPS …

Czech National Bank Raises Stock Holdings in Gilead Sciences, Inc. $GILD

The Czech National Bank increased its stake in Gilead Sciences (NASDAQ:GILD) by 4.6% in Q2, bringing its total holdings to 353,398 shares valued at $44.6 million. Gilead Sciences reported Q2 revenue of $7.8 billion, exceeding analyst expectations, despite a reported loss due to acquisition …

Merck & Company, Inc. (MRK) Stock Forecasts

Morningstar has released an analyst report for Merck & Co., Inc. (MRK), maintaining a steady quarter but raising the forecast for its biggest pipeline opportunity. Merck specializes in pharmaceutical products, with its immuno-oncology platform, notably Keytruda, being a significant sales contributor. The report provides …

Amarin Corporation PLC (AMRN) Stock News Today

PensionDanmark Pensionsforsikringsaktieselskab Buys 54,260 Shares of Merck & Co., Inc. $MRK

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Merck & Co., Inc. by 13.3% during the second quarter, purchasing an additional 54,260 shares, bringing their total holdings to 462,927 shares valued at $59.49 million. The article also details recent analyst ratings, highlighting both positive developments like …

PensionDanmark Pensionsforsikringsaktieselskab Purchases 25,515 Shares of Gilead Sciences, Inc. $GILD

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.3% in the second quarter, acquiring an additional 25,515 shares and bringing their total holdings to 233,799 shares valued at $29.54 million. This article details various institutional investor activities, recent positive and negative …

Sarasin & Partners LLP Sells 49,029 Shares of Merck & Co., Inc. $MRK

Sarasin & Partners LLP has reduced its stake in Merck & Co., Inc. by selling 49,029 shares, now holding 736,662 shares valued at approximately $94.7 million. Despite this sale, institutional investors collectively own 76.07% of the company. Wall Street analysts maintain a "Moderate Buy" …

NewEdge Advisors LLC Buys 231,715 Shares of Gilead Sciences, Inc. $GILD

NewEdge Advisors LLC significantly increased its stake in Gilead Sciences (NASDAQ:GILD) by 144.2% in the first quarter, purchasing an additional 231,715 shares, bringing their total holdings to 392,435 shares valued at $54.7 million. This move is part of broader institutional investor activity in GILD …

Organon & Co (OGN) Stock News Today

Assenagon Asset Management S.A. Raises Stock Holdings in Merck & Co., Inc. $MRK

Assenagon Asset Management S.A. significantly increased its stake in Merck & Co., Inc. by 263.7% in the second quarter, now owning 2,702,992 shares valued at $347.33 million. The article also details other institutional investor activity, Merck's financial performance, recent dividend announcement, and various analyst …

Czech National Bank Acquires 27,039 Shares of Merck & Co., Inc. $MRK

The Czech National Bank increased its stake in Merck & Co., Inc. (NYSE:MRK) by 4.0% in the second quarter, acquiring an additional 27,039 shares to hold a total of 703,007 shares valued at $90,336,000. Several other institutional investors also adjusted their holdings in MRK. …

Assenagon Asset Management S.A. Boosts Stock Holdings in Gilead Sciences, Inc. $GILD

Assenagon Asset Management S.A. significantly increased its stake in Gilead Sciences, Inc. by 346.5% in the second quarter, now owning 2,287,888 shares worth $289,052,000. Other institutional investors also adjusted their positions in the biopharmaceutical company. Gilead Sciences reported strong Q2 revenue of $7.8 billion, …

Merck lifts 2026 outlook as profits surge &Bio-Techne deal strengthens growth push

Merck has raised its full-year guidance for 2026 after reporting stronger-than-expected second-quarter results, driven by growth in life science, rare diseases, and semiconductor solutions. The company's proposed acquisition of Bio-Techne Corporation is expected to further bolster its leadership in high-growth life science markets. Merck …